Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Across all cancers: a drug is placed once, at the highest stage it reaches anywhere. Representative drugs are those with the most active trials at that stage.
86 drugs · 711 active trials
22 drugs · 918 active trials
347 drugs · 19,206 active trials
Outside the funnel: Withdrawn 25. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 17 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Mifamurtide | Approved | Phase 2 | 2 | 1 | 0 | 3 | 1 | EU | Mar 6, 2009 | 2014-10 |
| Pentostatin | Approved | Phase 3 | 1 | 0 | 2 | 33 | 3 | CA, US | Oct 11, 1991 | Sep 6, 1994 |
| Bexarotene | Approved | Phase 4 | 1 | 1 | 3 | 27 | 4 | EU, US | Dec 29, 1999 | 1998-10 |
| Porfimer | Approved | Phase 3 | 1 | 0 | 4 | 24 | 10 | CA, EU, US | Dec 27, 1995 | 1995-02 |
| Sulindac | Approved | Phase 3 | 1 | 0 | 2 | 22 | 1 | US | Mar 3, 1988 | 1996-08 |
| Toremifene | Approved | Phase 4 | 1 | 1 | 12 | 20 | 2 | EU, US | Feb 14, 1996 | 1991-07 |
| Lonafarnib | Approved | Phase 3 | 1 | 0 | 2 | 18 | 1 | US | Nov 20, 2020 | 1998-10 |
| Glasdegib | Approved | Phase 3 | 1 | 0 | 4 | 16 | 4 | CA, EU, US | Nov 21, 2018 | Mar 3, 2010 |
| Margetuximab | Approved | Phase 3 | 1 | 0 | 2 | 9 | 2 | US | Dec 16, 2020 | 2010-07 |
| Tirbanibulin | Approved | Phase 4 | 1 | 1 | 1 | 7 | 2 | US | Dec 14, 2020 | 2007-11 |
| Sertraline | Approved | Phase 3 | 1 | 1 | 1 | 5 | 24 | US | Dec 30, 1991 | Mar 1, 2004 |
| Histamine | Approved | Phase 3 | 1 | 0 | 2 | 4 | 1 | EU | Oct 7, 2008 | 1998-07 |
| Meloxicam | Approved | Phase 4 | 1 | 1 | 1 | 4 | 4 | US | Jun 1, 2004 | 2004-02 |
| Thyrotropin Alfa | Approved | Phase 4 | 1 | 1 | 1 | 4 | 8 | EU, US | Nov 30, 1998 | 1997-12 |
| Anagrelide | Approved | Phase 3 | 1 | 0 | 1 | 2 | 11 | CA, EU, US | Mar 14, 1997 | Nov 14, 2017 |
| Hydroxycarbamide | Approved | Phase 3 | 1 | 1 | 1 | 2 | 2 | EU | Jun 29, 2007 | Oct 25, 2019 |
| Interferon Beta-1a | Approved | Phase 2 | 1 | 1 | 0 | 2 | 22 | CA, US | May 17, 1996 | Jan 10, 2023 |
| Crisantaspase | Approved | Early Phase 1 | 1 | 1 | 0 | 1 | 2 | CA, EU | May 3, 2023 | Oct 22, 2025 |
| Ibritumomab Tiuxetan | Approved | Phase 4 | 0 | 0 | 7 | 28 | 8 | CA, EU, US | Feb 19, 2002 | 2001-08 |
| Ibandronic Acid | Approved | Phase 4 | 0 | 0 | 11 | 18 | 6 | EU | Jun 25, 1996 | 2003-04 |
| Peginterferon Alfa-2a | Approved | Phase 4 | 0 | 0 | 7 | 18 | 14 | CA, US | Oct 16, 2002 | 2003-09 |
| Dacomitinib | Approved | Phase 3 | 0 | 0 | 1 | 17 | 1 | US | Sep 27, 2018 | Oct 11, 2005 |
| Catumaxomab | Approved | Phase 3 | 0 | 0 | 3 | 14 | 4 | CA, EU | Feb 10, 2025 | 2004-09 |
| Chloroquine | Approved | Phase 4 | 0 | 0 | 1 | 14 | 1 | US | Dec 11, 1974 | 2005-01 |
| Methyl Aminolevulinate | Approved | Phase 4 | 0 | 0 | 6 | 13 | 1 | CA | Jun 16, 2009 | Oct 18, 1999 |
| Teprotumumab | Approved | Phase 2 | 0 | 0 | 0 | 9 | 1 | US | Jan 21, 2020 | 2006-04 |
| Melphalan Flufenamide | Approved | Phase 3 | 0 | 0 | 2 | 8 | 1 | EU | Aug 17, 2022 | 2013-07 |
| Temoporfin | Approved | Phase 2 | 0 | 0 | 0 | 8 | 1 | EU | Oct 24, 2001 | 1998-10 |
| Cinacalcet | Approved | Phase 4 | 0 | 0 | 2 | 6 | 9 | EU, US | Mar 8, 2004 | 2001-04 |
| Padeliporfin | Approved | Phase 3 | 0 | 0 | 1 | 5 | 1 | EU | Nov 10, 2017 | 2008-09 |
| Valrubicin | Approved | Phase 3 | 0 | 0 | 2 | 5 | 3 | CA, US | Sep 25, 1998 | 1993-11 |
| Alitretinoin | Approved | Phase 3 | 0 | 0 | 1 | 4 | 2 | EU, US | Feb 2, 1999 | 1996-05 |
| Amphotericin B | Approved | Phase 4 | 0 | 0 | 2 | 4 | 1 | US | Apr 29, 1992 | 1996-01 |
| Radium Ra-223 Dichloride | Approved | Phase 2 | 0 | 0 | 0 | 3 | 2 | CA, US | May 15, 2013 | Jun 25, 2014 |
| Chlormethine | Approved | Phase 2 | 0 | 0 | 0 | 2 | 2 | CA, EU | Mar 3, 2017 | Dec 7, 2021 |
| Glatiramer | Approved | Phase 1 | 0 | 0 | 0 | 1 | 11 | CA, US | Dec 20, 1996 | Jul 26, 2019 |
| Interferon Beta-1b | Approved | Phase 1 | 0 | 0 | 0 | 1 | 7 | CA, US | Jul 23, 1993 | — |
| Sodium Iodide 131 I | Approved | Phase 2 | 0 | 0 | 0 | 1 | 8 | CA | Jun 30, 2009 | Sep 15, 2021 |
| Bacillus Calmette-Guérin (bcg) - Strain Russian Bcg-I | Approved | — | 0 | 0 | 0 | 0 | 1 | CA | Aug 30, 2021 | — |
| Bacillus Calmette-Guerin (bcg) Strain Tice | Approved | — | 0 | 0 | 0 | 0 | 1 | CA | Dec 31, 1995 | — |
| Dacomitinib | Approved | — | 0 | 0 | 0 | 0 | 1 | US | Sep 27, 2018 | — |
| Dasatinib (dasatinib (s)-Propylene Glycol) | Approved | — | 0 | 0 | 0 | 0 | 6 | CA | Sep 16, 2021 | — |
| Irbesartan | Approved | — | 0 | 0 | 0 | 0 | 3 | US | Sep 30, 1997 | — |
| Leniolisib | Approved | — | 0 | 0 | 0 | 0 | 2 | CA, US | Mar 24, 2023 | — |
| Peginterferon Beta-1a | Approved | — | 0 | 0 | 0 | 0 | 7 | CA, US | Aug 15, 2014 | — |
| Radium Ra223 dichloride | Approved | — | 0 | 0 | 0 | 0 | 1 | EU | Nov 13, 2013 | — |
| Trastuzumab Deruxtecan | Approved | — | 0 | 0 | 0 | 0 | 21 | US | Dec 20, 2019 | — |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.